FAQ Studies

What studies are currently running or are planned for the future?

Currently, a number of studies in different CytoSorb-indications (such as cardiac surgery, sepsis, pancreatitis) are running in cooperation with well renowned scientific partners

  • More information can also be obtained...

Currently, a number of studies in different CytoSorb-indications (such as cardiac surgery, sepsis, pancreatitis) are running in cooperation with well renowned scientific partners

  • More information can also be obtained from:
  • Further clinical trials are also in preparation.
  • In the United States, a pilot study for the preparation of the US approval of CytoSorb in cardiac surgery has been launched. FDA approval for this study has been granted

What is the available data on safety and efficacy?

Comprehensive pre-clinical studies were conducted. (Venkataraman 2004 / Peng 2008 and 2014).

  • In two clinical multi-center trials, involving 100 and 50 patients, the effective and safe elimination of cytokines...

Comprehensive pre-clinical studies were conducted. (Venkataraman 2004 / Peng 2008 and 2014).

  • In two clinical multi-center trials, involving 100 and 50 patients, the effective and safe elimination of cytokines by CytoSorb has been demonstrated.
  • Publication of both trials is in preparation.
  • In all previous clinical publications the safety of the procedure has been recognized.
  • After currently over 20,000 single applications in patients, it can be assumed that the CytoSorb therapy is very safe and well tolerated.

How can I help to generate evidence for CytoSorb therapy?

CytoSorbents is a company with a strong medical and scientific focus. Our team comprises of physicians and biologists who focus is primarily to deal with clinical research.

  • If you...

CytoSorbents is a company with a strong medical and scientific focus. Our team comprises of physicians and biologists who focus is primarily to deal with clinical research.

  • If you have ideas regarding clinical trials, please contact us.
  • In order to obtain more in-depth knowledge and experience of the effects, benefits and the safety of the CytoSorb-Therapy, an international registry has been initiated and launched in collaboration with the Study Centre of the University Hospital Jena, Germany, headed by Prof. Frank Brunkhorst
  • We would you like to invite you to register and participate in this project by sharing your clinical experience in CytoSorb application.
    For further information please visit www.cytosorb-registry.com